Olema Pharmaceuticals Inc Aktie News

SAN FRANCISCO, 2. Sept. 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. („Olema“ oder „Olema Oncology“, Nasdaq: OLMA), ein im klinischen Stadium befindliches biopharmazeutisches Unternehmen mit Fokus auf Entdeckung, Entwicklung und Kommerzialisierung zielgerichteter Therapien für Brustkrebs und darüber hinaus, gab heute bekannt, dass das Unternehmen im Zusammenhang mit der Ernennung von Ja...

SAN FRANCISCO, 04. Aug. 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. („Olema“ oder „Olema Oncology“, Nasdaq: OLMA), ein biopharmazeutisches Unternehmen im klinischen Stadium mit Fokus auf Entdeckung, Entwicklung und Kommerzialisierung zielgerichteter Therapien für Brustkrebs und darüber hinaus, gab heute bekannt, dass das Unternehmen Aktienoptionen an sieben neue Mitarbeiter gewährt hat...

SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares ...

Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a cli...

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) --...

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 7 th Annual O...

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares ...

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Prakash Raman, Ph.D., to its Board of Directors.